Following are a development budget including Q4 2013, and reaching mid-year 2015 with $19.42 million total spend projected, as well as the consolidated income statement for all core business units over a 10-year period.
"Investing in NeuroMama, Ltd. (OTC: NERO) carries a high level of risk, and may not be suitable for all investors. The high degree of risk and reward can work against you as well as for you. Before deciding to invest in NERO you should carefully consider your investment objectives, level of experience, and risk appetite. The possibility exists that you could sustain a loss of some or all of your initial investment and therefore you should not invest money that you cannot afford to lose. You should be aware of all the risks associated with investing in fast growth companies, and seek advice from an independent financial adviser if you have any doubts. ( Important Disclosure )"